Skip to main content

Advertisement

SpringerLink
Log in

Can tamoxifen therapy be optimized for patients with breast cancer on the basis of CYP2D6 activity assessments?

  • Practice Point
  • Published:

From Nature Clinical Practice Oncology

View current issue Sign up to alerts

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Stearns V et al. (2003) Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst 95: 1758–1764

    Article  CAS  Google Scholar 

  2. Goetz MP et al. (2005) Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol 23: 9312–9318

    Article  CAS  Google Scholar 

  3. Jin Y et al. (2005) CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst 97: 30–39

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Petra Roberts, Associate Editor, Nature Clinical Practice.

Author information

Author notes

  1. Institute for Drug Development, Cancer Therapy and Research Center, Alice P McDermott Building, 14960 Omicron Drive, San Antonio, TX 78245–3217, USA ctakimot@idd.org

Authors and Affiliations

  1. CH Takimoto is the Director of Pharmacology at the Institute for Drug Development, Cancer Therapy & Research Center, and Clinical Associate Professor at the University of Texas Health Science Center, San Antonio, TX, USA.,

    Chris H Takimoto

Authors
  1. Chris H Takimoto
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

The author declares no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Takimoto, C. Can tamoxifen therapy be optimized for patients with breast cancer on the basis of CYP2D6 activity assessments?. Nat Rev Clin Oncol 4, 152–153 (2007). https://doi.org/10.1038/ncponc0716

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncponc0716

  • Springer Nature Limited

Search

Navigation